Clinical trials
PSMA clinical trials
Below are recruiting psma clinical trials, each written for real people, not researchers. We’re tracking 199 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05613738Recruiting
Test drug for advanced prostate cancer with high PSMA scans
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
Beijing, Beijing MunicipalityAges 18–80 - NCT06600802Recruiting
Lu-PSMA treatment for advanced prostate cancer
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
Clermont-FerrandAges 18 years+ - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
Brooklyn, New YorkAges 18–99 - NCT06462495RecruitingEarly Phase 1
Comparing two PSMA PET/CT scans for prostate cancer
This trial compares two types of PET/CT scans (using different radioactive tracers) to see which is better at finding prostate cancer, tracking its return, or spotting spread. It's for people with prostate cancer or those being checked for recurrence after treatment.
Hefei, AnhuiAges 18–90 - NCT06462508RecruitingEarly Phase 1
Comparing two PET scans for prostate cancer detection
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
Hefei, AnhuiAges 18–90 - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+ - NCT05228106Recruiting
PSMA scan using 68Ga-PSMA-617 PET/CT
This study looks at a PSMA-targeted PET/CT scan using 68Ga-PSMA-617 for tumors that show a specific marker (PSMA). It’s meant to help confirm or evaluate suspected or known PSMA-expressing tumors in real-life clinical practice.
Sherbrooke, QuebecAges Any age - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT05919329RecruitingPhase 4
PSMA scan changes after starting hormone therapy for prostate cancer
This study looks at how a prostate-specific scan marker (PSMA) changes after you start or continue hormone therapy. It may help doctors better understand who responds and how quickly prostate cancer biology shifts during treatment.
Portland, OregonAges 18 years+ - NCT07208240RecruitingPhase 1/Phase 2
PSMA-targeted radiation before prostate removal for advanced cancer
This trial tests giving a radioactive drug (PSMA-targeted) before surgery for prostate cancer that has spread locally but not to other parts of the body. The goal is to see if it helps lower the risk of the cancer coming back.
Petah TikvaAges 18 years+ - NCT07621692RecruitingPhase 1
New radioactive therapy for advanced prostate cancer
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
TaipeiAges 20 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT04402151RecruitingPhase 2
PSMA scan–guided targeted radiation for higher-risk prostate cancer
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
New York, New YorkAges 21–90 - NCT04987086Recruiting
68Ga PSMA PET-CT for kidney cancer spread
This study checks whether a special PET-CT scan using 68Ga PSMA can better find where renal cell carcinoma has spread. It may help doctors plan the right next steps by confirming suspected metastases on CT.
Lanzhou, GansuAges 18–90 - NCT06059469RecruitingPhase 2
PSMA scan for advanced triple-negative breast cancer
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
BrusselsAges 18 years+ - NCT06923657Recruiting
PSMA PET/MRI for guiding biopsy after negative MRI
This study tests whether a special type of PET/MRI scan (PSMA PET/MRI) can help doctors find hidden prostate cancer in men who have a rising PSA but previous negative biopsies and a non-suspicious MRI. It aims to improve detection without skipping needed treatment.
Fuzhou, FujianAges 30–85 - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT06835244Enrolling by invitation
Study of PSMA PET/CT scans for non-prostate cancers
This study looks at how well a special scan (PSMA PET/CT) works for people with cancers other than prostate cancer. If your doctor already scheduled this scan for your care, you may be able to help researchers learn more about its accuracy.
BolognaAges 18 years+ - NCT07054346RecruitingPhase 1
Radioactive drugs before prostate surgery for high-risk prostate cancer
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
San Francisco, CaliforniaAges 18 years+ - NCT07698535RecruitingPhase 2
Blood test to guide early stopping of prostate cancer therapy
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
Seattle, WashingtonAges 18 years+ - NCT07316686RecruitingPhase 1
Study of docetaxel and lutetium-PSMA for first-line treatment of metastatic prostate cancer
This trial tests a combination of chemotherapy (docetaxel) and a targeted radiation therapy (lutetium-PSMA) as a first treatment for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to see if this combination is safe and effective.
São PauloAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma?
- Yes. Clin2 currently lists 199 recruiting psma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.